Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
14G2a-gelonin
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intraperitoneal, Intratumoral, Intrathecal, Parenteral
01
Overview
**14G2a-gelonin** is an experimental GD2-directed immunotoxin consisting of the anti-disialoganglioside GD2 monoclonal antibody 14G2a chemically conjugated through an SPDP linker to gelonin, a plant-derived ribosome-inactivating protein. The antibody targets GD2-expressing neuroectodermal tumor cells, while internalized gelonin inhibits protein synthesis through ribosomal RNA depurination. In published in-vitro work, the conjugate retained 14G2a immunoreactivity, complement-dependent cytotoxicity, and antibody-dependent cellular cytotoxicity, and showed direct cytotoxicity against human melanoma cell lines with substantially greater activity than unconjugated gelonin. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11038823/))
- Other names
- 14.G2a-gelonin14G2a-gelonin14G2a-gelonin immunotoxingelonin-14G2agelonin14G2agelonin 14G2a
02
Targets
GD280S ribosome (Ribosome and ribosomal components)
Beyond the preview
Go deeper on 14G2a-gelonin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 14G2a-gelonin.